Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Novo Nordisk A/S (NVO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Novo Nordisk ADR's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
127.35 +1.56    +1.24%
14:51:49 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 2,461,110
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 125.99 - 127.90
Novo Nordisk ADR 127.35 +1.56 +1.24%

NVO Ratios

 
Assess the performance of Novo Nordisk ADR (NVO). This table contains core financial ratios such as Price-to-Earnings (P/E ratio), Return-On-Investment (ROI), Earnings per share (EPS), Dividend yield and others based on Novo Nordisk A/S's latest financial reports. Compare the performance metrics of Novo Nordisk ADR (NVO) against the industry averages.
InvestingPro Advanced Ratios
Name Company Industry
   
P/E Ratio TTM 46.21 98.48
Price to Sales TTM 16.65 8.16
Price to Cash Flow MRQ 35.51 37.02
Price to Free Cash Flow TTM 46.53 97.23
Price to Book MRQ 36.29 16.51
Price to Tangible Book MRQ 83.61 -76.19
   
Profitability: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Gross margin TTM 84.6% 69.98
Gross Margin 5YA 83.81% 48.62
Operating margin TTM 44.77% 10.8
Operating margin 5YA 43.03% -21.54
Pretax margin TTM 45.07% 10.9
Pretax margin 5YA 41.25% -28.5
Net Profit margin TTM 36.03% 10.31
Net Profit margin 5YA 33.1% -31.93
   
Revenue/Share TTM 52.1 169.99
Basic EPS ANN 18.67 17.18
Diluted EPS ANN 18.62 17.1
Book Value/Share MRQ 23.9 153.94
Tangible Book Value/Share MRQ 10.35 18.81
Cash/Share MRQ 3.23 25.04
Cash Flow/Share TTM 24.43 27.91
   
Management Effectiveness: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Return on Equity TTM 88.07% 32.33
Return on Equity 5YA 76.6% 38.73
Return on Assets TTM 30.12% 10.5
Return on Assets 5YA 30.33% 10.98
Return on Investment TTM 68.52% 20.97
Return on Investment 5YA 67.92% 22.07
   
EPS(MRQ) vs Qtr. 1 Yr. Ago MRQ 63.15% 577.82
EPS(TTM) vs TTM 1 Yr. Ago TTM 52.32% 28.33
5 Year EPS Growth 5YA 18.52% 5.92
Sales (MRQ) vs Qtr. 1 Yr. Ago MRQ 36.95% 10.07
Sales (TTM) vs TTM 1 Yr. Ago TTM 31.26% 7.98
5 Year Sales Growth 5YA 15.74% 8.1
5 Year Capital Spending Growth 5YA 21.78% 8.83
   
Quick Ratio MRQ 0.56 0.89
Current Ratio MRQ 0.82 1.28
LT Debt to Equity MRQ 14.99% 125.89
Total Debt to Equity MRQ 25.34% 132.87
Efficiency    
Asset Turnover TTM 0.84 0.58
Inventory Turnover TTM 1.27 2.7
Revenue/Employee TTM 3.67M 7.91M
Net Income/Employee TTM 1.32M 1.16M
Receivable Turnover TTM 4.49 4.7
   
Dividend Yield ANN 0.61% 1.8
Dividend Yield 5 Year Avg. 5YA 1.76% 2.89
Dividend Growth Rate ANN 226.16% 35.08
Payout Ratio TTM 37.96% 206.52
TTM = Trailing Twelve Months  5YA = 5-Year Average  MRQ = Most Recent Quarter
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced valuation and financial ratios for in-depth analysis of company financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NVO Comments

Write your thoughts about Novo Nordisk A/S
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Grumpy Cat
Grumpy Cat Apr 18, 2024 9:38AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this company was doing so well, what happened.
Jackson Nahm
Jackson Nahm Apr 18, 2024 9:38AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Profit taking imo, it’ll go higher
Keith Dunkelbarger
Keith Dunkelbarger Apr 17, 2024 6:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A1C down from 9.4 to 6.2 and weight down from 254 to 238 with Ozempic. Lot of flatulence and air freshener.
yeongjin white
yeongjin white Mar 14, 2024 11:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
300 by 2024
roy reyes
roy reyes Feb 05, 2024 8:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
gonna dominate the obesity space with Catalent mreger
Karsten Vester
Karsten Vester Feb 01, 2024 4:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
450 by 2030.. Serving 1 mill custumors now and there are 800 mill. U do the math..
D Petersen
D Petersen Jan 29, 2024 8:45PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
NVO should advance nicely Wednesday on good earnings and a bright 2024 outlook.
Karsten Vester
Karsten Vester Nov 28, 2023 9:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Eli is very keen on disrupting NN but they dont even have cardio vascular studies or a candidate for next generation but NN dos. They are way behind so dont be disrupted by their lobby activities ….
In the Money
In the Money Oct 21, 2023 7:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
140+ eoy
Paul Chan
Paul Chan Oct 21, 2023 7:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Not with the recent deaths from Ozempic.
Karsten Vester
Karsten Vester Oct 21, 2023 7:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Come with dome documentstion dude. Far out to say
dar dar
dar dar Oct 13, 2023 12:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
like all things, eventually we will know the outcome
Karsten Vester
Karsten Vester Oct 03, 2023 11:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Now all small investors seems to fanzy ophra Winfrey to dictate the benefits and dowfalls in pharma industry. What a world with celebraties and you tupers now rules the world. S… t.. f… up woman - you dont know what you are talking about and go back to girlish problems and your billions..
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email